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“Drink plenty of fluids”: a systematic review of evidence
for this recommendation in acute respiratory infections
Michelle P B Guppy, Sharon M Mickan, Chris B Del Mar
Doctors often recommend drinking extra fluids to
patients with respiratory infections. Theoretical ben-
efits for this advice are replacing insensible fluid losses
from fever and respiratory tract evaporation, correct-
ing dehydration from reduced intake, and reducing the
viscosity of mucus.1 2 To many this advice is self evident
and justified on the basis that even if the benefit is
uncertain, or at best small, at least it is harmless.
However, there are theoretical reasons for
increased fluid intake to cause harm. Antidiuretic hor-
mone conserves fluid by stimulating water reabsorp-
tion from the renal collecting ducts. Increased
antidiuretic hormone secretion has been reported in
adults and children with lower respiratory tract
infections of bronchitis, bronchiolitis, and pneumonia
of viral and bacterial aetiology.3 4 It is uncertain if this
also occurs in upper respiratory tract infections.
Several mechanisms have been proposed for this
increased hormone secretion, acting through fever,
hypoxia, hypercarbia, pain, emotion, or nausea.
Secretion may be stimulated by a resetting of osmostat
receptors to lower levels.3 Also, lung hyperinflation and
pulmonary infiltrates may stimulate hormone secre-
tion by causing a false perception of hypovolaemia by
intrathoracic receptors.4 This would be in keeping with
findings that antidiuretic hormone secretion in
pneumonia increases proportionally with the extent of
lung parenchymal involvement.3
Giving extra fluids while antidiuretic hormone
secretion is increased may theoretically lead to
hyponatraemia and fluid overload. Clinical symptoms
of hyponatraemia are irritability, confusion, lethargy,
coma, and convulsions. Fluid restriction may be appro-
priate management to prevent this.
Methods and results
To determine whether recommending increased fluids
was beneficial or harmful, we undertook a systematic
review and posed three questions:
Does recommending increased fluid intake for acute
respiratory infections improve duration and severity of
symptoms?
Are there adverse effects from this recommendation?
Are any benefits or harm related to site (upper or lower
respiratory tract) or severity of illness?
Using the Cochrane Acute Respiratory Infections
Group search strategy, together with additional terms
(see bmj.com for details), we did a conventional search
of the Cochrane Central Register of Controlled Trials,
Medline (1966-2003), Embase (1974-2003), and
Current Contents (1966-2003). We examined refer-
ences of relevant papers and contacted experts in the
subject.
We found no randomised controlled trials compar-
ing increased and restricted fluid regimens in patients
with respiratory infections. Two prospective prevalence
studies reported hyponatraemia at rates of 31% and
45% for children with moderate to severe pneumonia
Extra details about the search strategy used and tables detail-
ing results from other studies appear on bmj.com
Studies showing hyponatraemia in non-dehydrated patients with respiratory infections
Study
No of
patients Age Diagnosis Exclusions
Serum sodium level
(mmol/l) Serum or urine osmolality
Symptoms associated with
low sodium level
Dhawan et al
19922
100 1 month-12 years Pneumonia Clinical dehydration 31 patients
had Na <130
Serum dilute in 29,
concentrated in 2 (probable
dehydration)
4 died, Na <125 mmol/l
Shann et al
19851
73 ≥1 month Pneumonia Clinical dehydration 33 patients had
Na <134
— Hyponatraemia 2-3 times
more frequent with severe
pneumonia
Rivers et al
19815
4 6-8 weeks and 6 months 3 bronchiolitis,
1 pneumonia
— 3 patients had
Na 114-124
Concentrated urine, or not
maximally dilute urine
Seizures in one patient with
bronchiolitis
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(see table).1 2 None of these children showed clinical
signs of dehydration. Symptoms associated with hypo-
natraemia were not reported, but four children with a
serum sodium below 125 mmol/l died during one
study.
We also found several case series in which patients
with respiratory infections developed hyponatraemia, of
which some were symptomatic (table).5 These patients
were all successfully treated with fluid restriction.
Comment
We found data to suggest that giving increased fluids to
patients with respiratory infections may cause harm. To
date there are no randomised controlled trials to pro-
vide definitive evidence, and these need to be done.
Until we have this evidence, we should be cautious
about universally recommending increased fluids to
patients, especially those with infections of the lower
respiratory tract.
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Effect of statin treatment for familial
hypercholesterolaemia on life assurance: results of
consecutive surveys in 1990 and 2002
H A W Neil, T Hammond, D Mant, S E Humphries Topic: 183;163
One of the concerns often raised about genetic testing
is the possibility that a positive result (or even
disclosing that the test has been taken) may result in
difficulty in obtaining life assurance. Currently the UK
insurance industry has declared a moratorium on
requiring genetic tests from applicants,1 but since DNA
based tests offer a definitive, highly specific diagnosis
they are likely eventually to replace less specific clinical
diagnostic criteria for many inherited disorders. Early,
presymptomatic treatment may increase life expect-
ancy by preventing or reducing the risk of developing
the disease or associated complications. However, if life
assurance policy premiums do not adequately reflect
the reduction in mortality with treatment relatives of
affected probands may be deterred from being tested.
We examined how life assurance companies have
responded to the improvement in the prognosis of
heterozygous familial hypercholesterolaemia with
statin treatment.2
Familial hypercholesterolaemia is an autosomal
dominant disorder, inherited on average by one in two
children of an affected parent. The prevalence in the
United Kingdom is about 1:500, but at least three
quarters of cases remain undiagnosed.3 It is usually
caused by mutations in the gene for the low density
lipoprotein (LDL) receptor that result in accumulation
of plasma cholesterol and substantially increased
coronary mortality. Without effective treatment the
cumulative risk of a coronary event is at least 50% in
men and 30% in women by the age of 60 years.4 With
statin treatment, however, the standardised mortality
ratio for coronary heart disease for such patients aged
20-59 years has more than halved over the past
decade.2
Participants, methods, and results
We conducted a survey of 41 life assurance companies
in 19905 and repeated it in 2002 by sending the same
questionnaire to 26 companies still underwriting term
life assurance. They were asked to assess a fictional
proposal for a 20 year policy (paying benefit only on
death) by applying an excess mortality rating defined
as the percentage increase over the assumed rate of
mortality. In the follow up survey companies were
asked to assess the rating before and after statin treat-
ment. The applicant was a normotensive (120/80 mm
Hg), non-smoking, 30 year old man taking no
medication, with a body mass index of 22.1 kg/m2 and
a normal resting electrocardiogram, whose father had
had a non-fatal myocardial infarction aged 45 years.
He had no other family history of heart disease, other
medical history of note, or tendon xanthomata on
examination. The results of the lipid profile (mmol/l)
were total cholesterol 11.4, high density lipoprotein
(HDL) cholesterol 1.7, triglycerides 1.3, and calculated
LDL cholesterol 9.1; and the presumptive diagnosis
was familial hypercholesterolaemia. On treatment with
atorvastatin 80 mg daily his total cholesterol concen-
tration was 6.2 mmol/l (compared with 10.7 mmol/l
on cholestyramine prescribed in 1990).
The figure shows the excess mortality ratings
applied. Because two companies would assess propos-
als only from patients receiving statin treatment statis-
tical comparisons were restricted to 24 companies. The
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